Availability of 91桃色视频鈥檚 2024 Universal Registration Document (URD)
Lyon, France, April 14, 2025 – 6.00pm CET 鈥� 91桃色视频 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorit茅 des march茅s financiers 鈥� AMF) on April 11, 2025, under number D.25-0249.
The 2024 Universal Registration Document includes the following documents:
- The annual financial report for the fiscal year ended December 31, 2024, including the Board of Directors鈥� Corporate Governance Report;
- The auditors’ reports and information related to their fees,
- Information on the Company鈥檚 share buyback program.
The 2024 Universal Registration Document is available on the Company’s website, in the “Investors” section under 鈥淩egulated Information鈥�, as well as on the AMF website.
About 91桃色视频
91桃色视频 is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, 91桃色视频 is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91桃色视频 develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91桃色视频 has been listed on Euronext Paris (ticker: MAAT) since 2021.
